Phytomedics Inc. and Henkel KGaA Enter Collaboration
DAYTON, N.J., Feb. 6 /PRNewswire/ -- Phytomedics Inc., a private life sciences company focused on the discovery and development of novel plant-derived healthcare products, is pleased to announce the signing of an agreement with Henkel KGaA, one of the world's largest chemical companies, to develop innovative and proprietary botanical ingredients for cosmetic applications.
"We are very pleased to be working with Henkel KGaA, a world leader in developing novel body care and cosmetic products," said Dr. Bertold Fridlender, CEO of Phytomedics Inc. "Henkel's expertise in these areas complements Phytomedics' unique and proprietary discovery and development technologies. This synergy presents an opportunity for the commercialization of a new generation of novel, safe and effective botanical cosmetic ingredients."
Phytomedics is a unique life sciences company merging plant biology, biotechnology and medicinal chemistry for the development of innovative healthcare products. Phytomedics conducts its R&D under the leadership of Professor Ilya Raskin, Ph.D., at the Biotech Center of Rutgers University, who is also a founder and Chairman of the Company. Phytomedics has a broad research and licensing agreement with Rutgers University that allows the Company to exclusively license its core technologies and products.
Phytomedics has developed a broad range of plant-based technologies targeted for the discovery and manufacturing of novel pharmaceuticals, nutritional and health care products. Phytomedics has several products in various stages of development, including products for viral, auto-immune, inflammatory and cardiovascular diseases, cancer, diabetes, erectile dysfunction and sleep improvement, some of which are in clinical trials.
About Phytomedics Inc.
Phytomedics Inc. uses a broad and innovative proprietary technology platform to discover, develop and manufacture novel, multi-component and multi-functional botanical therapeutics such as botanical drugs and nutraceuticals, as well as recombinant proteins. Through this proprietary technology platform, the Company has produced a pipeline of pharmaceutical and nutraceutical lead compounds, several of which are in clinical development. Founded by Professor Ilya Raskin, Ph.D., Phytomedics Inc. conducts most of its R&D at the Biotech Center of Rutgers University.
SOURCE: Phytomedics Inc.
65 Stults Road, Dayton, NJ 08810